Ethical and Participant Safety Considerations
Protecting people before protecting data
Ethics content clusters around three frameworks: the Belmont principles (respect for persons, beneficence, justice), the Declaration of Helsinki, and the GCP and regional regulations that operationalize them. For each, move from principle to practice: respect for persons becomes informed consent plus additional protections for those with diminished autonomy; beneficence becomes favourable risk–benefit assessment and ongoing safety monitoring; justice becomes fair subject selection and fair distribution of burdens and benefits.
Know the elements of a valid consent discussion: purpose, procedures, risks and discomforts, expected benefits, alternatives, confidentiality, compensation and treatment for injury, voluntariness and the right to withdraw, and whom to contact. Consent is a process, not a signature; participants need time, and re-consent is required when new information could affect willingness to continue. Vulnerable populations - children, pregnant women, prisoners, cognitively impaired adults, economically disadvantaged groups - generally require additional safeguards and, for children, assent alongside parental permission.
Safety vocabulary is heavily tested. An adverse event is any untoward medical occurrence; a serious adverse event meets a specific regulatory definition and triggers expedited reporting, typically within 24 hours to the sponsor and then to regulators within defined clocks. Causality is assessed separately from seriousness: a non-serious event can be related, and a serious event can be unrelated.
Trap: the therapeutic misconception - a participant believing trial participation is individualized to their personal benefit.
Rule of thumb: seriousness is defined by outcome, not severity. Worked example: a mild headache that keeps a participant in hospital an extra night is a serious adverse event because it prolonged hospitalization.